1. Breese GR, Baumeister AA, McCown TJ, Emerick SG, Frye GD, Crotty K, Mueller RA (1984) Behavioral differences between neonatal and adult 6-hydroxydopamine-treated rats to dopamine agonists: relevance to neurological symptoms in clinical syndromes with reduced brain dopamine. J Pharmacol Exp Ther 231:343–354
2. Breese GR, Baumeister A, Napier TC, Frye GD, Mueller RA (1985a) Evidence that D1 dopamine receptors contribute to the supersensitive behavioral responses induced by l-dihydroxyphenylalanine in rats treated neonatally with 6-hydroxydopamine. J Pharmacol Exp Ther 235:287–295
3. Breese GR, Napier TC, Mueller RA (1985b) Dopamine agonist-induced locomotor activity in rats treated with 6-hydroxydopamine at differing ages: functional supersensitivity of D1 dopamine receptors in neonatally lesioned rats. J Pharmacol Exp Ther 234:447–455
4. Breese GR, Duncan GE, Napier TC, Bondy SC, Iorio LC, Mueller RA (1987) 6-Hydroxydopamine treatments enhance behavioral responses to intracerebral microinjection of D1- and D2-dopamine agonists into the nucleus accumbens and striatum without changing dopamine antagonist binding. J Pharmacol Exp Ther 240:167–176
5. Brunton LL, Lazo JS, Parker KL (2006) Goodman & Gilman’s the Pharmacological Basis of Therapeutics, 11th edn. McGraw Hill, New York